Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A promising new partnership is targeting the root cause of brain diseases. TRIMTECH Therapeutics has inked a major research deal with Biogen to develop small molecule "degraders" that break down toxic protein clumps linked to neurodegenerative diseases. The collaboration could be worth up to $411 million for TRIMTECH, plus royalties.
A promising new partnership is targeting the root cause of brain diseases. TRIMTECH Therapeutics has announced a strategic research collaboration with Biogen to discover and develop small molecule protein degraders aimed at treating neurodegenerative diseases. The deal grants Biogen an option for a global exclusive license to any degraders developed, with Biogen taking the reins on further development and commercialization if the option is exercised.
TRIMTECH's platform is built on decades of academic research into TRIM21, a novel E3-ligase protein. Their proprietary TRIMTAC® and TRIMGLUE® degrader technologies are designed to penetrate the central nervous system and selectively break down the toxic protein aggregates and oligomers that drive many neurodegenerative conditions — a mechanism that could open entirely new small molecule treatment avenues for patients.
By the Numbers:
Why it matters: Neurodegenerative diseases remain among the hardest to treat, with few disease-modifying options available. Pairing TRIMTECH's novel degrader platform with Biogen's deep neuroscience expertise could accelerate the path to therapies that actually alter disease progression for millions of patients worldwide.